金吾财讯 | 卡莱尔伙伴（CSL）与Alentis Therapeutics达成独家全球合作，共同开发和商业化药物lixudbart，用于治疗罕见肾脏、肝脏及其他疾病。根据协议，CSL将向Alentis支付3.55亿美元首付款，Alentis还有资格获得最高12亿美元的商业里程碑付款；药物实现商业化后，全球利润由CSL分得55%，Alentis分得45%。CSL将资助lixudbart针对AAV-RPGN的二期试验及规划中的三期研究，同时推进FSGS、PSC的二期项目。lixudbart目前正在开展AAV-RPGN二期肾脏临床试验，AAV-RPGN是一种罕见自身免疫病，可造成肾功能快速衰退以及不可逆肾脏损伤。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.